Sunday 18 October 2026
Export IPSC’s income statement to Excel — free account
Century Therapeutics, Inc.
IPSC Healthcare Biotechnology
Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12,667.7%, EPS grew 55.3% and free cash flow grew 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.37
0.13
−8.67%
Follow IPSC
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
0.75 | 12.06 | 96.60 | 55.21 | — | — | — | — |
Altman Z-Score |
(3.39) | (3.91) | (2.68) | (0.71) | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(6.53) | (7.77) | (4.66) | 0.31 | — | — | — | — |
P/Operating CF |
(5.38) | (3.28) | (8.23) | (12.53) | — | — | — | — |
P/B ratio |
0.54 | 0.49 | 1.17 | 0.95 | — | — | — | — |
Price to Tangible BV |
0.69 | 0.62 | 1.17 | 0.95 | — | — | — | — |
EV/Sales |
(0.27) | (16.66) | 19.60 | (3.20) | — | — | — | — |
EV/EBITDA |
4.68 | 0.85 | 0.00 | 0.13 | — | — | — | — |
EV/Operating CF |
0.29 | 1.00 | (0.50) | (1.18) | — | — | — | — |
EV/FCF |
0.29 | 1.00 | (0.43) | 1.00 | — | — | — | — |
Quick Ratio |
5.79 | 1.46 | 9.68 | 10.58 | 14.24 | 6.25 | 27.28 | — |
Current Ratio |
5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 | — |
Net Debt/EBITDA |
17.95 | 1.46 | 1.25 | 2.43 | 2.31 | 1.26 | 4.12 | — |
Debt/Assets |
0.01% | 0.02% | 0.18% | 2.43% | 2.96% | 9.25% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.13 | 0.00 | — |
Asset Turnover |
0.38 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
10.84 | 0.87 | 0.65 | (0.11) | 0.93 | 0.77 | 0.07 | — |
Capex/Depreciation |
(0.08) | (0.02) | (1.50) | (3.50) | (11.09) | (6.58) | 0.00 | — |
Interest Coverage |
— | — | (271.38) | (93.59) | (74.42) | (141.46) | (33.11) | — |
| (5.98%) | (73.14%) | (56.07%) | (37.46%) | (66.13%) | 83.53% | (186.03%) | — | |
| (3.32%) | (35.46%) | (32.26%) | (28.34%) | (35.22%) | (40.03%) | (304.26%) | — | |
ROIC |
(25.79%) | 0.00% | (723.93%) | 0.00% | (31.83%) | (450.83%) | 0.00% | — |
Return on Tangible Assets |
(6.36%) | (100.12%) | (59.20%) | (35.13%) | (35.43%) | (65.28%) | (292.73%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
87.64% | 1,627.62% | 4,371.81% | 2,061.42% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
21.99% | 503.19% | 1,552.84% | 612.75% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.15 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.27% | 192.56% | 654.23% | 205.21% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.65 | 0.03 | 0.00 | 0.47 | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(14.00%) | (161.39%) | (62.91%) | (45.88%) | — | — | — | — |
Free Cash Flow Yield |
(120.99%) | (138.84%) | (47.28%) | (5.77%) | — | — | — | — |
Revenue per Share |
1.26 | 0.08 | 0.04 | 0.09 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.20) | (1.40) | (1.49) | 0.24 | (2.75) | (5.52) | (0.29) | — |
Capex per Share |
(0.01) | 0.00 | (0.23) | (0.53) | (1.39) | (1.31) | 0.00 | — |
Free Cash Flow per Share |
(1.21) | (1.40) | (1.72) | (0.29) | (4.14) | (6.83) | (0.29) | — |
Cash per Share |
1.35 | 2.41 | 2.91 | 5.46 | 6.88 | 10.12 | 1.49 | — |
Shareholders Equity per Share |
1.84 | 2.05 | 3.11 | 5.24 | 12.23 | 9.80 | 2.88 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.84 | 2.05 | 3.11 | 5.24 | 12.23 | 9.80 | 2.88 | — |
Free Cash Flow |
(104.72) | (110.29) | (102.08) | (16.55) | (133.97) | (51.09) | (16.17) | — |
Working Capital |
100.54 | 64.27 | 159.15 | 289.90 | 212.50 | 66.69 | 81.13 | — |
Capital Expenditures |
(0.85) | (0.15) | (13.74) | (30.60) | (44.97) | (9.82) | (2.46) | — |
Net Current Asset Value |
56.00 | 2.20 | 1.05 | 135.92 | 187.02 | 45.37 | 81.13 | — |
EV/EBIT |
1.77 | 0.79 | 0.00 | 0.12 | — | — | — | — |
Capex to Sales |
0.01 | 0.02 | 6.15 | 5.89 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.21 | 0.14 | 0.13 | 0.11 | 0.07 | 0.10 | 0.10 | — |
Cash ROIC |
(37.93%) | (31.45%) | (28.50%) | (2.63%) | (21.20%) | (32.14%) | (6.75%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 10.10 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,269.16 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 0.52 | 0.58 | 0.52 | 0.52 | — |
Average Payables |
3.92 | 2.91 | 4.10 | 6.53 | 7.84 | 4.82 | 4.82 | — |
Average Assets |
288.46 | 356.95 | 423.62 | 461.96 | 272.08 | 133.84 | 80.45 | — |
Average Common Equity |
160.15 | 173.06 | 243.74 | 349.49 | 144.91 | (64.14) | 131.58 | — |
Columns are period end dates